SNRPD1 and breast carcinoma: We next examined the sensitivity of TNBCs in response to doxorubicin, a common form of adjuvant chemotherapy for breast cancer treatment especially among TNBCs, after silencing SNRPD1 or SNRPE using MDAMB231 and HCC1937 as the cell models.